Category Archives: Cancer

Home / Cancer
2 Posts

In Fortune’s article “This Is What’s Missing in the Data Centric Approach to Cancer”, Barb Darrow discusses Erik Lefkofsky’s new venture.

Erik Lefkofsky is the co-founder and CEO Tempus. The startup was created to develop cancer databases to change cancer treatment into a combination of clinical data and molecular data.

He attended Fortune’s Brainstorm Health conference in San Diego where he discussed what’s missing from the current medical research system. Part of the problem today is that the researchers don’t have easy access to the data. For example, Lefkofsky states that “if you were to go into any of the cancer centers and ask who took Herceptin over two years and how they did, they’d need a grant and at least 90 days.”

Lefkosky started Tempus as a way to ameliorate the situation. Not only does it add technology to the existing electronic medical record, but it gathers the information and provides a unique approach to treatment. By creating a large aggregate data pool, the data for each individual can be used to discover patterns similarities between the results and the treatment.

The realization that drastic systematic change to cancer treatment was vital occurred after his wife was diagnosed with cancer. The constant trips to various doctors and specialists proved to be a disappointment when he realized that they simply didn’t have the data to interpret how the different treatments work for patients with similar molecular biology.

In addition to starting Tempus, Mr. Lefkofsky is also a co-founder of Groupon one of the largest global e-commerce marketplaces. He was a founding partner of Lightbank, a venture fund which invests in technology, and Uptake which is a leading analytics platform for some of the world’s most considerable industries.

Mr. Lefkosky and his wife are philanthropists who are dedicated to improving education, health care, human rights and the development of the arts. He founded Lefkosky Family Foundation with his wife in 2006 to improve high-impact programs that can drastically improve quality of life.

Learn More:


Getting good results after looking to find a solution to a health challenge like cancer takes the effort of experts in various specialties. Clay Siegall is among experts who have invested a lot to developing better cancer research methods. His idea is to come up with solutions that will put to an end the worry about cancer by developing reliable and strong cancer treatment methods. Although this is a field that has been around for many years, cancer research is yet to develop a fully reliable solution for the treatment of the disease.

Many companies and institutes have also chipped in to also do their part in the fight against cancer. Seattle Genetics, founded by Clay Siegall, has been key in delivering solutions that are developed with a focus on eliminating cancer. In a recent release, the company unveiled a new technology, the ADC Technology, which is quite promising and developed to offer an easier way of dealing with cancer. Through this technology, the cancer treatment process is made easier by the fact that it targets cancerous cells and kills them while sparing all healthy cells. This is unlike the popular methods that have been in use over the years since none could guarantee such a process. Several companies joined Seattle Genetics to support this revolutionary technology.

About Clay Siegall

Clay Siegall is a renowned scientist, who is the CEO and founder of a highly developed biotechnology company, Seattle Genetics. He supports research to develop highly effective and reliable cancer treatment methods and his company has helped in this space by producing the ADC Technology that makes treating cancer easier. He has also been working with the executives of other companies to chart ways forward and enter into strategic licenses that would allow joint effort in the fight to get a reliable cancer treatment method.

Between 1988 and 1991, Clay Siegall worked with the National Institute of Health and the National Cancer Institute. In 1991, he joined the Bristol-Meyers Squibb Pharmaceutical Institute, where he worked until 1997. In 1998, he founded Seattle Genetics and has been working as the CEO of the company.